Physician profile
Paul E Free
NPI 1962465179
$4,439.46
in general payments reported to CMS, 2019-2025
28 companies · $967 in 2025
The $967 reported for 2025 was more than what 79% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $699 · 2020: $855 · 2021: $577 · 2022: $279 · 2023: $288 · 2024: $775 · 2025: $967.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,930 · Education: $98.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,930.27 |
| Education | $98.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $1,536.67 | 2019-2025 | Scopis Ent |
| Genzyme Corporation | $674.75 | 2019-2025 | |
| Optinose US, INC. | $301.57 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $286.64 | 2019-2025 | Dupixent |
| Aerin Medical INC. | $282.74 | 2024-2025 | |
| Glaxosmithkline, LLC. | $250.05 | 2021-2025 | Nucala |
| Inspire Medical Systems, INC. | $199.15 | 2023-2025 | Inspire |
| Sanofi-Aventis U.S. LLC | $98.99 | 2024 | |
| Phathom Pharmaceuticals, INC. | $98.82 | 2025 | Voquezna |
| Intersect Ent, INC. | $83.68 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $79.31 | 2021-2022 | |
| Spirair, INC. | $77.70 | 2025 | Septalign, Turbalign |
| Kaleo, INC. | $66.27 | 2019-2022 | |
| Lilly USA, LLC | $50.36 | 2025 | Zepbound |
| Ars Pharmaceuticals Operations, INC. | $48.92 | 2025 | Neffy |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $39.59 | 2025 | Tezspire |
| Astrazeneca Pharmaceuticals Lp | $38.41 | 2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $34.39 | 2021 | |
| Resmed Corp | $33.69 | 2024-2025 | |
| Alk-Abello, INC | $27.79 | 2019-2022 | |
| Sanofi US Services INC. | $25.70 | 2024 | |
| Medtronic, INC. | $19.25 | 2021 | |
| Olympus America INC. | $17.91 | 2019 | |
| Hikma Pharmaceuticals USA | $17.05 | 2023 | Ryaltris |
| Baudax Bio INC. | $15.33 | 2022 | |
| Merck Sharp & Dohme LLC | $13.48 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.03 | 2021 | |
| Ambu INC. | $8.22 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Free listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.